AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Liver Fibrosis.

Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer.